Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026

The panel discusses landmark four-year overall survival data for mismatch repair–deficient endometrial cancer from the RUBY trial, presented earlier that day at SGO 2026 by Matthew Powell, MD. Dr. Thaker highlights the clinical counseling implications of the updated data, noting that patients who remain recurrence-free at 2 years face a roughly 90% probability of continued remission—a meaningful benchmark for managing patient anxiety during surveillance. Dr. Konecny and Dr. Wenham explore the shape of the survival curves, discussing whether the plateau observed in the mismatch repair–deficient population represents potential cure. The panel also examines the impact of high crossover rates to checkpoint inhibitor therapy on overall survival interpretation, concluding that early integration of dostarlimab in the frontline setting—rather than reserving it for later lines—is strongly supported by the durability of these outcomes.